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Introduction and historical background
Rheumatoid arthritis (RA) is a condition that is today
defined from a set of rather arbitrarily built criteria; those
criteria have been very helpful in identifying an entity for
which new therapies can be investigated, and such thera-
pies have lately been amazingly successful [1–4]. Despite
the continuing successes in developing therapies, the
underlying etiology of the disease, i.e. what eventually trig-
gers it and what genetic context allows it to progress,
have remained elusive. Consequently, only vague and
often scientifically unproven thoughts have been prevalent
in the public as well as in the professional arena when
ways of achieving primary or secondary prevention of the
disease are being considered.
In parallel, it has often been claimed that the disease is so
complicated and multifaceted that it may be an insur-
mountable task to elucidate the interactions between
genes and environment that ultimately determine whether
arthritis will occur and persist.
In one way, this situation of rapidly emerging new genetic
technologies in genetics but prevalent vague ideas of etiol-
ogy recalls the situation in the late 1980s, when new know-
ledge in the field of molecular immunology was paralleled
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Chapter summary
Understanding of how interactions between genes and environment contribute to the development of
arthritis is a central issue in understanding the etiology of rheumatoid arthritis (RA), as well as for
eventual subsequent efforts to prevent the disease. In this paper, we review current published data on
genes and environment in RA as well as in certain induced animal models of disease, mainly those in
which adjuvants only or adjuvants plus organ-specific autoantigens are used to induce arthritis. We
refer to some new data on environmental and genetic factors of importance for RA generated from a
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risk of seropositive but not of seronegative RA in smokers, and there are indications that this effect may
be due to a gene–environment interaction involving MHC class II genes. We also found an increased
risk of RA in individuals heavily exposed to mineral oils. This was of particular interest because mineral
oils are strong inducers of arthritis in certain rodent strains and because polymorphisms in human
genetic regions syntenic with genes predisposing for oil-induced arthritis in rats have now been shown
to associate with RA in humans. Taken together, our data support the notion that concepts and data
on gene-environment interactions in arthritis can now be taken from induced animal models of arthritis
to generate new etiological hypotheses for RA.
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by a rather vague understanding of the molecular pathol-
ogy of RA. It was frequently claimed then that the situation
was far too complicated to permit targeted therapy against
single components of the immune system, such as tumor
necrosis factor.
Taking the dramatic demonstration in recent years that
complicated problems such as finding targeted therapies
for RA can indeed be resolved by less complicated solu-
tions than hitherto for unravelling the remaining difficult
questions, we have contemplated the issue of gene–
environment interactions in RA and subsequent preventive
strategies towards the disease as being a reasonable
research effort to discuss at the current symposium and in
this supplement to Arthritis Research.
What is currently known about genes and
environment in the development of RA?
Knowledge about environmental influences on the devel-
opment of RA are of two kinds. The first — circumstantial —
kind of knowledge is derived from twin and kinship
studies, which all indicate that the genetic influence is
important but probably less influential than environmental
effects. Concordance between monozygotic twins with
regard to RA has been reported to be between 10% and
15% [5], or even lower [6]. The second — more direct —
kind of knowledge derives from case–control or cohort
studies on the influence of distinct agents or events on
RA, in which exposure to a number of agents have been
reported to be associated with RA. Such agents include
smoking, which has been shown to be a risk factor in
several studies [7,8], silica [9,10] and blood transfusion
[11]. Taken together, the knowledge of environmental
agents predisposing to RA remains rudimentary. Virtually
no molecular mechanisms have been proposed for how
such agents may work, and no work has been presented
to show that agents associated with RA in humans cause
arthritis in an animal model of RA.
Although genetic influences on RA have been more exten-
sively studied than environmental effects, current knowl-
edge is nevertheless sketchy, even with regard to the most
studied genetic region, the major histocompatibility
complex (MHC). Thus, it has been shown that different
MHC alleles are associated with RA in different popula-
tions [12], and also that the degree of association between
a certain allele and RA varies depending on which popula-
tion of RA patients is selected. That the arthritis denoted
RA is associated with certain HLA-DR4 alleles in studies
on White populations from the USA or Western Europe
but with other alleles in Japanese or Jewish populations
[12] clearly indicates that other genes interact with the
MHC genes in mediating the susceptibility to arthritis.
The demonstration of only a moderate association
between HLA-DRB1*0401 in a group of RA patients from
a population-based survey [13] but a much higher associ-
ation in RA populations in hospital settings indicates that
HLA-DRB1*0401 may be as much a severity factor as a
susceptibility factor. Because the association between
MHC class II alleles and RA is the most convincing evi-
dence of a role of HLA-DR restricted T-cell activation in
the pathogenesis of RA, these studies also indicate that
there is a marked heterogeneity within an RA population
as to the role of such T-cell activation, which is smaller in
early, mild arthritis.
Other genes contributing to susceptibility to RA have so far
been sought mainly in cytokine-associated genes. Several
associations have been described between functionally rel-
evant cytokine promotor genes and RA [14–17]. Also, the
wide genome scans that have been reported from North
America and Europe have suggested that gene regions
outside the MHC may be relevant, though the relevant
genes within these regions have not yet been identified.
Finally, very few efforts have hitherto been directed towards
the investigation of the interactions between genes and
environment in the pathogenesis of RA. The rest of this
review is concerned with a discussion of how such investi-
gations may be conducted, given the current knowledge of
genes and environment and given that leads regarding
both potential environmental triggers and genes important
for disease may be derived from relevant animal models.
What are relevant animal models for RA, and
how can these be used to generate concepts
about gene–environment interactions in
arthritis?
In the light of the background given above, there are four
prerequisites for relevant animal models for RA. First, the
disease should be inducible by nonspecific triggers (com-
parable with cigarette smoking or silica exposure in
humans). In addition, the models must be characterized by
certain genetic contexts in which MHC class II genes may
act as both susceptibility and severity factors. They should
also be highly variable in disease course, which should
often involve tissue destruction and chronicity. And finally,
they should sometimes but not always involve autoimmune
reactions towards both cartilage-specific and ubiquitously
expressed autoantigens.
Here we restrict ourselves to describing a number of such
models in the rat, as that species appears to offer models
for several chronic inflammatory diseases that are more
similar to the comparable disease in man than is the case
in mouse models [18]. Two basic features are critical to
the understanding of the arthritis models in the rat. First,
triggers can be of several different kinds, including both
nonspecific ‘nonimmunogenic’ substances — such as
glucans (from yeast), lipopolysaccharides (from bacteria),
squalene (endogenous) or mineral oil (exogenous)S33
[19,20] — and more specific cartilage-derived antigens
such as collagen II or cartilage oligomeric matrix protein
(COMP) [18,21] (for an overview, see Table 1). In some
strains, exposure to one of the nonspecific stimuli (given
intracutaneously or sometimes even percutaneously) may
by itself cause arthritis [22–24], whereas in others, stimu-
lation with both nonspecific stimuli and cartilage-derived
molecules are prerequisites for the development of arthri-
tis [25]. In some typical situations, the addition of anticarti-
lage immunity to the effects of nonspecific stimuli may
change the course of the disease from monophasic and
nondestructive in character to chronic and destructive.
The second feature of the rat models is the involvement of
many polymorphic genes in determining the character of
the disease course after a given stimulus. Thus, a non-
specific stimulus may produce a monophasic, nondestruc-
tive disease in one strain but a chronic, relapsing–remitting,
severely destructive disease in another [26]. Interestingly, it
has recently been shown that certain sets of genes may be
most instrumental in determining the overall susceptibility
to disease, while other sets may preferentially determine
the chronicity and still others may determine destructive-
ness. Taken together, these findings show that there is no
single disease phenotype associated with one given trig-
gering agent. Rather, both exposure to simple stimulating
adjuvants and combinations of adjuvants and autoantigens
can give rise to a highly variable disease course, depend-
ing on the overall genetic make-up.
In recent years, polymorphic genes determining the
phenotype of arthritis in rats have been studied quite
intensively and a number of gene regions have been iden-
tified that influence susceptibility to arthritis and the
destructiveness and severity of the disease. Further pro-
duction of inbred strains, congenic for small parts of the
identified candidate gene regions, have permitted the
identification of smaller gene regions that appear to
contain the respective susceptibility or severity genes
[20]. An interesting aspect of this work is that the same
genetic context that predisposes for development of adju-
vant arthritis induced by single compounds (oil, pristane,
squalene) also predisposes to the development of colla-
gen-induced arthritis, in which the additional presence of
certain MHC class II genes is mandatory for the develop-
ment of disease [20,26–28].
It thus appears that a certain set of genes may determine
the response of the innate immune system to adjuvants,
sometimes resulting in arthritis without the addition of
further stimuli. The addition of a specific immunity to self-
antigens such as collagen will in these cases make the
arthritis more severe and destructive. In other genetic con-
texts, the combination of immunity to self-antigens and a still
strong and genetically determined response to adjuvants is
necessary to induce disease. Such a multiple-hit mode
would explain why similar sets of ‘adjuvant-associated’
genes influence development of both adjuvant arthritis and
collagen-induced arthritis, and how, in addition, mainly
MHC-related genes influence the development of collagen-
induced arthritis. So far, no single susceptibility gene has
been definitely identified using this method, but research in
the field is moving so rapidly that this could happen soon.
Taken together, these animal data indicate that exposure
to nonspecific triggers affecting mainly the innate immune
system may in certain genetic contexts suffice to induce
arthritis, whereas in other genetic contexts participation of
the adaptive immune system is mandatory. In addition, it is
reasonable to believe that different combinations of these
mechanisms may be important in different phases of arthri-
tis development.
Can concepts of mechanisms, potential
triggers and potential candidate genes
generated in experimental rodent models be
meaningfully transferred and tested in
humans?
A classic question in research on all inflammatory humans
diseases is whether experience from animal models is at
all relevant and valuable for the human diseases, in partic-
ular when defined triggers are used in animals, and where
almost nothing is known about whether there are triggers
in humans, and if there are, what they might be. The alter-
native in human disease, however, would be to be
restricted to whole-genome scans in the search for rele-
vant disease genes, and to a very unfocused investigation
of environmental factors in the search for potential triggers
of disease. In the face of this choice, we have set out to
study both candidate genes and environmental factors,
taking our lead from the animal experience discussed in
the previous section.
Thus, a case–control study has been initiated in Sweden,
using an ongoing population-based, multicenter surveil-
lance program for early incident cases of RA as the basis
for identification of cases, and a well-established system
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Table 1
Arthritogenic agents
Simple, 
nonimmunogenic  Molecules giving rise to specific 
agents immune responses
Glucans Collagens II, IX, XI
Pristane Cartilage oligomeric matrix protein (COMP)
Mineral oils Proteoglycans
Squalene
Bacterial DNA (CpG)S34
for identification of controls matched for age, sex and area
of residence (P Stolt et al., manuscript submitted for publi-
cation). For these individuals, both cases and controls,
extensive information has been accumulated about envi-
ronmental exposure preceding the onset of arthritis for
cases and during a comparable period for controls. Also,
blood samples for genotyping, serology and other labora-
tory investigations have been accumulated from cases as
well as controls at the time of onset for cases (and the
same time for controls). The future strategy is obviously to
test potential effects of environmental agents in a conven-
tional case–control setting and simultaneously to try to
use information about synteny between rodent (here rat)
genes and human genes to identify relevant candidate
genes or candidate gene regions for RA. Polymorphisms
within these candidate regions should be investigated as
to their influence both on susceptibility to RA and on the
course of the disease. So far, the research team has accu-
mulated 1200 cases and 1200 controls and has started
to test the viability of the approach.
The first environmental exposure we set out to investigate
was smoking, which has previously been shown to be a
risk factor for RA, although quantification of the risk has
been somewhat ambiguous and we do not know whether
the risk is in any way confined to individuals with a certain
genetic make-up. The first investigation (P Stolt et al.,
manuscript submitted for publication) thus showed a sig-
nificantly increased relative risk of RA in ever-smokers
compared with never-smokers (RR = 1.5), that this risk
was confined to individuals who smoked for a long time,
and that smoking was a risk factor only for rheumatoid-
factor (RF)-positive RA, but not for RF-negative RA. The
latter observations suggested that there might be a
sequence of events whereby smoking induces production
of RF, which in turn contributes to the development of RA.
The other – and not exclusive – possibility would be that
RF positivity is merely a marker for a certain genotype, and
that mainly individuals with this genotype would have an
increased risk of RA after smoking. As RF-positive RA has
in several studies been linked to presence of certain HLA-
DR allotypes, mainly the ‘shared epitope’, we thus also
stratified our patients according to whether they were
shared epitope (SE)-positive. The increased relative risk of
developing RA in smokers was restricted to the group of
individuals who carried the SE genes (L Padyukov et al.,
manuscript in preparation). Although still confined to
results from a subanalysis of the first 500 patients investi-
gated in our RA cohort, this preliminary finding may be the
first documentation of a gene–environment interaction in
development of RA, and thereby it may also be of value in
supporting the general scope of our research approach.
A second striking finding in our analysis of odds ratios for
the development of RA after various environmental expo-
sures relates to mineral oils. An odds ratio of 1.9 was
found for individuals exposed to hydraulic oils (almost all
men). Because exposure to mineral oil by subcutaneous
injection or the percutaneous route was previously shown
to induce arthritis in certain rodent strains (see above),
this observation in RA suggests that disease mechanisms
similar to those in rodents may be involved in some cases
of RA. We have not yet been able to investigate to what
extent the risk associated with this exposure to oil is
restricted to individuals with a certain genetic constitution.
However, a recent family study in the UK showed an
increased risk of RA in individuals carrying a certain allelic
form of a gene region on human chromosome 17, defined
by means of synteny with a genetic region that determines
susceptibility to oil-induced arthritis in rats [29,30]. This
observation is, as far as we know, the first to identify a
gene region of importance for the development of RA fol-
lowing leads from animal studies on non-MHC arthritis
susceptibility gene regions.
Hopefully, these two observations may pave the way for a
future investigation of whether exposure to oil confers an
even higher risk of RA in individuals carrying certain alleles
of this 17q region, but, more importantly, may also make
possible functional studies of how a particular potential
trigger of arthritis influences the immune system in individ-
uals carrying a certain set of susceptibility genes (see
summary picture of strategy in Fig. 1).
When and in which patients is there a role for
organ-specific autoimmunity?
The animal model studies indicate that specific autoimmune
reactions to organ-specific antigen, such as collagen II, may
contribute to both the onset and the severity of arthritis, but
that this phenomenon is restricted to individuals carrying
specific MHC class II alleles. Transferred to the human situ-
ation, such findings indicate that specific immunity to organ-
specific antigens should be performed in the context of
genetic characterization of subgroups of patients. So far,
this has been done to some extent for collagen II and on a
very small scale for other organ-restricted antigens.
However, an immune response to collagen II in both T and
B cells has been reported in individuals carrying the SE
genes, albeit at a rather low frequency [31–33]. Further-
more, HLA-DRB1*0401 transgenic mice have been shown
to be susceptible to collagen-induced arthritis and to
mount a strong immune response to collagen II [34]. Taken
together, these data thus indicate that collagen autoimmu-
nity may after all contribute to arthritis in a genetically
defined subset of RA patients. The identification of this
subset by genetic and other means may permit us to inves-
tigate further which environmental and genetic factors favor
the onset of a collagen immunity, and also to investigate
how collagen immunity may add to the effects of other
agents, for example adjuvants, in making RA more severe
(Fig. 2 presents a hypothetical model of this situation).
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Concluding remarks
We provide arguments for, but not really against, the use of
data and ideas generated in induced animal models to gen-
erate viable research strategies to study gene–environment
interaction of importance for human arthritis. Privileged by
the opportunity to contribute to a volume on arthritis
research in connotation with one of the most importance
breakthroughs in therapy of RA, we have felt it possible to
present this unbalanced but hopefully productive view on
how to attack still underlying fundamental problems in
rheumatology. We believe that the encouragement given to
rheumatology from the progress in therapeutics will greatly
help us in solving also these further questions about origin
and potential future prevention of the disease.
Glossary of terms
RF = rheumatoid factor; SE = shared epitope.
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